Zagars GK - Search Results

1

Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer.

Pollack A, Zagars GK, el-Naggar AK, Terry NH. Pollack A, et al. Among authors: zagars gk. Urology. 1994 Nov;44(5):711-8. doi: 10.1016/s0090-4295(94)80213-0. Urology. 1994. PMID: 7526527

2

Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study.

Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A. Little DJ, et al. Among authors: zagars gk. Urology. 2003 Oct;62(4):707-13. doi: 10.1016/s0090-4295(03)00504-1. Urology. 2003. PMID: 14550448 Clinical Trial.

3

The relationship of local control to distant metastasis in muscle invasive bladder cancer.

Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Pollack A, et al. Among authors: zagars gk. J Urol. 1995 Dec;154(6):2059-63; discussion 2063-4. J Urol. 1995. PMID: 7500458

4

Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.

Pollack A, Zagars GK, el-Naggar AK, Gauwitz MD, Terry NH. Pollack A, et al. Among authors: zagars gk. Cancer. 1994 Apr 1;73(7):1895-903. doi: 10.1002/1097-0142(19940401)73:7<1895::aid-cncr2820730721>3.0.co;2-0. Cancer. 1994. PMID: 7511039

5

The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy.

Zagars GK, Geara FB, Pollack A, von Eschenbach AC. Zagars GK, et al. Cancer. 1994 Apr 1;73(7):1904-12. doi: 10.1002/1097-0142(19940401)73:7<1904::aid-cncr2820730722>3.0.co;2-6. Cancer. 1994. PMID: 7511040

6

Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome.

Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Zagars GK, et al. J Urol. 1994 May;151(5):1330-3. doi: 10.1016/s0022-5347(17)35244-8. J Urol. 1994. PMID: 7512663

7

The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment.

Zagars GK, Pollack A. Zagars GK, et al. Radiother Oncol. 1994 Feb;30(2):121-7. doi: 10.1016/0167-8140(94)90040-x. Radiother Oncol. 1994. PMID: 7514308

8

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.

Pollack A, Zagars GK, Kavadi VS. Pollack A, et al. Among authors: zagars gk. Cancer. 1994 Jul 15;74(2):670-8. doi: 10.1002/1097-0142(19940715)74:2<670::aid-cncr2820740220>3.0.co;2-8. Cancer. 1994. PMID: 7518341

9

Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.

Sands ME, Zagars GK, Pollack A, von Eschenbach AC. Sands ME, et al. Among authors: zagars gk. Urology. 1994 Aug;44(2):215-20. doi: 10.1016/s0090-4295(94)80134-7. Urology. 1994. PMID: 7519381

10

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.

Kavadi VS, Zagars GK, Pollack A. Kavadi VS, et al. Among authors: zagars gk. Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):279-87. doi: 10.1016/0360-3016(94)90005-1. Int J Radiat Oncol Biol Phys. 1994. PMID: 7523340

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters